1-(5-乙基-2-吡啶基)乙酮 | 286411-85-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(5-乙基-2-吡啶基)乙酮
• 英文名称: 1-(5-ethyl-2-pyridinyl)ethanone
• 英文别名: 1-(5-ethyl-pyridin-2-yl)-ethanone；1-(5-ethyl-[2]pyridyl)-ethanone；1-(5-Aethyl-[2]pyridyl)-aethanon；2-acetyl-5-ethyl-pyridine；1-(5-Ethylpyridin-2-yl)ethanone
• CAS: 286411-85-6
• 化学式: C₉H₁₁NO
• mdl: MFCD09263903
• 分子量: 149.192
• InChiKey: UQGODFDLOPSSFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(5-乙基-2-吡啶基)乙酮 在 sodium ethanolate 、 一水合肼 作用下， 生成 2,5-二乙基吡啶
  参考文献：
  名称：

  Prostenik; Filipovic, Arhiv za Kemiju, 1946, vol. 18, p. 3,6

  摘要：

  DOI：
• 作为产物：
  描述：

  5-乙基吡啶-2-羧酸 在 盐酸 、 sodium 作用下， 生成 1-(5-乙基-2-吡啶基)乙酮
  参考文献：
  名称：

  Prostenik; Filipovic, Arhiv za Kemiju, 1946, vol. 18, p. 3,6

  摘要：

  DOI：

文献信息

• The development of improved syntheses of PPARγ-sparing, insulin sensitizing thiazolidinedione-ketones
  作者：Steven P. Tanis、Jerry R. Colca、Timothy T. Parker、Gerald D. Artman、Scott D. Larsen、Robert C. Gadwood、James R. Zeller

  DOI：10.1016/j.tetlet.2019.07.022

  日期：2019.8

  Ketones 2 (MSDC-0160) and 3 (MSDC-0602) had been selected for clinical development, however their initial syntheses were considered suboptimal for application deep into clinical trials. Difficulties ranging from the nature of the starting material, alcohol oxidation problems, epoxide opening regioisomeric issues, and endgame ketone redox problems had been encountered. Direct ketone introduction/maintenance

  已经选择了酮2（MSDC-0160）和酮3（MSDC-0602）进行临床开发，但是它们的初始合成被认为不是最适合用于临床试验。遇到了各种困难，包括原料的性质，醇的氧化问题，环氧化物的打开区域异构问题以及最终的酮氧化还原问题。直接引入酮/维护被期望的最大效率和收敛被发现是关键取决于亲核物种（酸度13，18）和使用前或后alkylative肟基醚/酮肟保护的（见下文）。实现了2（MSDC-0160）和3（MSDC-0602）合成的总产率分别从20％（2）和31％（3）提高到44％（2）和59％（3）。
• [EN] SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS<br/>[FR] NOUVELLE SYNTHÈSE POUR DES COMPOSÉS DE THIAZOLIDINEDIONE
  申请人：METABOLIC SOLUTIONS DEV CO LLC

  公开号：WO2012021467A1

  公开（公告）日：2012-02-16

  The present invention provides novel methods for synthesizing PPARy sparing compounds, e.g., thiazolidinediones, that are useful for preventing and/or treating metabolic disorders such as diabetes, obesity, hypertension, and inflammatory diseases.

  本发明提供了一种合成PPARγ保留化合物（例如噻唑烷二酮）的新方法，用于预防和/或治疗代谢性疾病，如糖尿病、肥胖、高血压和炎症性疾病。
• NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES
  申请人：Pandey Bipin

  公开号：US20140088127A1

  公开（公告）日：2014-03-27

  A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine.

  一种制备噻唑烷二酮类药物的新工艺，首选为吡格列酮。还描述了参与其合成的新中间体，以及用于它们的制备和在医药中的应用的工艺。
• Novel process to prepare pioglitazone via several novel intermediates
  申请人：Pandey Bipin

  公开号：US20080300282A1

  公开（公告）日：2008-12-04

  A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine.

  一种制备噻唑烷二酮的新工艺，优选为吡格列酮。同时还描述了参与其合成的新中间体，以及用于其制备和在医学上的应用的工艺。
• Amidopyrazole Derivative
  申请人：Kanaya Naoaki

  公开号：US20070219210A1

  公开（公告）日：2007-09-20

  A platelet coagulation inhibitor which inhibits neither COX-1 nor COX-2 is provided. The inhibitor is a compound represented by general formula (I): wherein Ar 1 and Ar 2 independently represent a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents, or a phenyl group optionally substituted with 1 to 3 substituents; R1 represents a lower acyl group, carboxyl group, a lower alkoxy carbonyl group, a lower alkoxy group, a lower alkyl group optionally substituted with 1 or 2 substituents, a carbamoyl group optionally substituted with 1 or 2 substituents, an oxamoyl group optionally substituted with 1 or 2 substituents, an amino group optionally substituted with 1 or 2 substituents, a 4- to 7-membered alicyclic heterocyclic group optionally substituted with 1 or 2 substituents, a phenyl group optionally substituted with 1 to 3 substituents, or a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents; and R2 represents hydrogen atom, a halogeno group, or the like.

  提供了一种血小板凝血抑制剂，它既不抑制COX-1也不抑制COX-2。该抑制剂是由通式（I）表示的化合物：其中Ar1和Ar2独立地表示一个5-或6-成员的芳香杂环基团，可选地取代1至3个取代基，或一个苯基，可选地取代1至3个取代基；R1表示较低的酰基，羧基，较低的烷氧羰基，较低的烷氧基，较低的烷基，可选地取代1或2个取代基的氨基甲酰基，可选地取代1或2个取代基的草酰基，可选地取代1或2个取代基的氧代草酰基，可选地取代1或2个取代基的氨基，可选地取代1或2个取代基的4-至7-成员脂环杂环基团，可选地取代1或2个取代基的苯基，或可选地取代1至3个取代基的5-或6-成员芳香杂环基团；R2表示氢原子，卤素基或类似物。